Yonsei University · Medicine
Professor Jun Yong Park's research lab specializes in hepatology and viral hepatitis, with a strong focus on chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC). The lab investigates host-virus interactions, non-invasive fibrosis assessment using elastography, and the dynamic virological and serological responses to antiviral therapy. Key research directions include optimizing treatment strategies through biomarkers such as quantitative HBsAg and HBeAg, and evaluating innovative locoregional therapies like hepatic arterial infusion chemotherapy (HAIC) for advanced HCC.
Figures are computed from collected data and may differ slightly.
Both qHBsAg and qHBeAg decreased significantly with ETV therapy. The baseline qHBsAg levels and the on-treatment decline of qHBeAg in HBeAg(+) patients were proven to be highly useful in predicting VR and SR, respectively. The determination of qHBsAg and qHBeAg can help us to select the appropriate strategy for the management of patients with CHB. However, the dynamic interplay between qHBsAg, qHBeAg, and HBV DNA during antiviral therapy remains to be elucidated.
HAIC with high-dose 5-FU and cisplatin given for 3 days achieved effective and safe results in patients with advanced HCC. Therefore, repetitive short-course HAIC with high-dose 5-FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC.
Different cutoff LSM values according to ALT level and combination with age-spleen-platelet ratio index can enhance the performance of LSM in CHB, regardless of ALT level.
LSM can be a useful predictor of LRE development in CHB patients showing histologically advanced liver fibrosis.
Current treatment guidelines suggest that antiviral therapy be considered for chronic hepatitis B (CHB) patients with high viral load if a biopsy shows significant liver disease despite alanine aminotransferase (ALT) levels two times or less than the upper limit of normal (ULN). We evaluated the histological findings in CHB patients with high viral load and persistently normal or slightly elevated serum ALT levels. Between January 2003 and June 2006, 105 consecutive treatment-naive patients with
Open papers in the app to read, cite, and organize with AI.
